Document Detail

Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
MedLine Citation:
PMID:  23026982     Owner:  NLM     Status:  In-Data-Review    
Cox-2 inhibitors have been identified as promising candidates for cancer therapy. Several studies have recently proposed the use of celecoxib in long-term low-intensity chemotherapy protocols for recurrent tumors. However, drug-induced hypersensitivity reactions may force discontinuation of the medication and, thus, significantly complicate successful care. Here, we report on celecoxib desensitization after a celecoxib-induced skin reaction, thereby allowing the continuation of temozolomide/celecoxib chemotherapy in a young patient with recurrent astrocytoma.
Guido J Burbach; Peter Vajkoczy; Torsten Zuberbier
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  23     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1118-20     Citation Subset:  IM    
Departments of aDermatology, Venereology, and Allergy bNeurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of the Medicare posthospitalization skilled nursing benefit in the last 6 months of life.
Next Document:  Infusion therapy in the home care setting: a clinical competency program at work.